Indian Generics Case Worries Humanitarian Agencies

Pharmaceutical company Novartis is making final arguments to India's Supreme Court in the final stages of its six-year legal battle to overturn the Indian patent office's rejection of its drug Gleevec  used for treating leukemia. The case has much broader consequences since much of the developing world depends on cheaper copies of expensive patented medicines that are manufactured in India. About $10 billion in Indian generics are exported annually. For example, Gleevec (or Glivec, as it is branded outside the US) can cost as much as $70,000 a year in the United States while the Indian generic versions cost about $2,500 a year....Read Full Post
Source: About.com Biotech Biomedical - Category: Biotechnology Source Type: news